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Candida glabrata is a major pathogenic yeast in humans that is known to rapidly acquire
resistance to triazole and echinocandin antifungal drugs. A mutator genotype (MSH2
polymorphism) inducing a mismatch repair defect has been recently proposed to be
responsible for resistance acquisition in C. glabrata clinical isolates. Our objectives
were to evaluate the prevalence of antifungal resistance in a large cohort of patients
in Saint-Louis hospital, Paris, France, some of whom were pre-exposed to antifungal
drugs, as well as to determine whether MSH2 polymorphisms are associated with an
increased rate of fluconazole or echinocandin resistance. We collected 268 isolates
from 147 patients along with clinical data and previous antifungal exposure. Fluconazole
and micafungin minimal inhibition concentrations (MICs) were tested, short tandem
repeat genotyping was performed, and the MSH2 gene was sequenced. According to
the European Committee on Antimicrobial Susceptibility breakpoints, 15.7% of isolates
were resistant to fluconazole (MIC > 32 mg/L) and 0.7% were resistant to micafungin
(MIC > 0.03 mg/L). A non-synonymous mutation within MSH2 occurred in 44% of
the isolates, and 17% were fluconazole resistant. In comparison, fluconazole resistant
isolates with no MSH2 mutation represented 15% (P = 0.65). MSH2 polymorphisms
were associated with the short tandem repeat genotype. The rate of echinocandin
resistance is low and correlates with prior exposure to echinocandin. The mutator
genotype was not associated with enrichment in fluconazole resistance but instead
corresponded to rare and specific genotypes.
Keywords: Candida glabrata, antifungal resistance, echinocandin, fluconazole, MSH2, mutator genotype,
genotyping, short tandem repeat
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INTRODUCTION
Ascomycetous yeasts are the most common agents responsible
for fungal infections in humans, and the incidence of Candida
spp. infections has significantly increased over the last two
decades (Lass-Flörl, 2009). Up to 17% of all ICU-acquired
infections are caused by Candida spp. and are associated with
a high mortality rate, which is showing increasing trends (Lass-
Flörl, 2009; Lortholary et al., 2014). Candida glabrata is the
second most-common bloodstream Candida species isolated in
Europe and North-America (Pfaller and Diekema, 2007). Even
though C. glabrata cannot form hyphae, a well-known virulence
factor in C. albicans, its pathogenic traits and rapid acquisition of
resistance, especially to azoles and echinocandins, are a matter
of concern (Cleveland et al., 2012; Wisplinghoff et al., 2014;
Vale-Silva and Sanglard, 2015). This yeast has intrinsically low
susceptibility to fluconazole, with 10–30% of C. glabrata isolates
harboring high fluconazole MICs (MIC >32 mg/L) (Pfaller and
Diekema, 2007).
The mechanisms leading to high fluconazole or echinocandin
MICs have been documented (Jensen et al., 2015; Vale-Silva and
Sanglard, 2015). Most published epidemiological data report the
emergence of echinocandin resistance in C. glabrata, especially in
North America. The prevalence of echinocandin resistance varies
depending on the geographical location, with Europe showing
lower rates (0–9%) (Klotz et al., 2016) compared to the rates
of 0–25% in the USA (Vallabhaneni et al., 2015). Furthermore,
echinocandin resistance seems to have increasing prevalence over
time (Alexander et al., 2013; Farmakiotis et al., 2014) and to
be associated with a higher mortality rate (Alexander et al.,
2013; Shields et al., 2015). C. glabrata develops echinocandin
resistance through target mutation of the 1,3-beta-D-glucan
synthase gene encoded by FKS1 and FKS2 genes (Alexander et al.,
2013; Perlin, 2015). Simultaneous resistance to all echinocandins
(caspofungin, micafungin, and anidulafungin) has been detected
using various susceptibility-testingmethods after specific hotspot
polymorphisms develop.
The reason whyC. glabrata acquires resistancemore rapidly to
multiple antifungal classes than other Candida species is unclear
and has been attributed to its haploid genome. However, Healey
et al. recently suggested that a defect in DNA repair may account
for accelerated emergence of various genetic changes responsible
for drug resistance (Healey et al., 2016). The aim of this study is
to evaluate the factors associated with the isolation of fluconazole
or echinocandin resistance in a single French hospital using all
isolates recovered over a specific period of time. The association
between resistance and antifungal drug pre-exposure as well as
MSH2 sequence type, representing potential mutator genotypes,
were carefully studied after all isolates were genotyped with
short tandem repeat markers to identify individual strains of
C. glabrata.
MATERIALS AND METHODS
Ethics Statement
Saint-Louis Hospital, Paris, France, is a tertiary university
hospital with major clinical activities in hematology, renal
transplantation, burn unit, and oncology. This study was a non-
interventional study with no change in the usual procedures.
Biological material and clinical data were obtained only for
standard diagnostics following physicians’ prescriptions with no
specific sampling. According to French Health Public Law (CSP
Art L1121-1.1), such a protocol does not require the approval
of an ethics committee and is exempted from specific informed
consent application.
Isolates and Patients
All consecutive C. glabrata isolates recovered from June 2015
to February 2016 in our mycology laboratory (Saint-Louis
Hospital, Paris, France) were prospectively collected. A total
of 268 isolates were obtained from various anatomical sites of
147 patients (1–19 isolates per patient, Table 1). All isolates
were primary cultured on CHROMagar R© Candida Medium
(Becton Dickinson, Heidelberg, Germany) incubated at 37◦C
for 5 days and identified as C. glabrata using matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF, Vitek MS; Biomérieux, Marcy l’Etoile, France).
For each isolate, a minimum of 5 colonies were picked together
and stored at −80◦C. DNA was extracted using a MagNA Pure
LC apparatus (Roche, Mannheim, Germany) according to the
manufacturer’s recommendations and stored at−20◦C until PCR
was performed. In our hospital, each antifungal drug prescription
TABLE 1 | Characteristics of patients and isolates.
Characteristics Patients (n = 147) Isolates (n = 268)
Age (years), median (range) 62 (18–91)
Sex, male/female ratio 0.91
Sample origin, n (%)
Abdominal (surgery) 8 (3.0)
Blood 6 (2.2)
Feces 46 (17.2)
Mouth 50 (18.7)
Respiratory 81 (30.2)
Skin 22 (8.2)
Uro-vaginal 55 (20.7)
Hospital Unit, n (%)
Hematology 34 (23.1) 63 (23.5)
ICU 38 (25.9) 102 (38.1)
Others 75 (51) 103 (38.4)
Patients treated with voriconazole or
posaconazole (1t first day of
treatment–day of sampling)
>7 days 41 (15.3)
<7 days 11 (4.1)
Not treated 216 (80.6)
Patients treated with caspofungin (1t
first day of treatment–day of sampling)
>7 days 23 (8.6)
<7 days 9 (3.4)
Not treated 236 (88.1)
ICU, Intensive Care Unit.
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except for fluconazole is recorded by the pharmacy department
with the corresponding indication. This registry has been used
to analyze the duration of previous antifungal exposure for each
C. glabrata isolate.
Susceptibility Testing
Although our hospital does not prescribe micafungin, we tested
for it instead of caspofungin according to the recommendations
of the Clinical and Laboratory Standards Institute (CLSI)
and European Committee on Antimicrobial Susceptibility
(EUCAST) (Arendrup et al., 2013). Since interlaboratory
variability occurs with caspofungin testing (Espinel-Ingroff
et al., 2013), micafungin or anidulafungin can serve as testing
surrogates for the echinocandin class to assess resistance (Pfaller
et al., 2014a,b; Perlin, 2015). In addition, high micafungin MIC
results have been shown to correlate with the occurrence of
FKS mutations, which is also the case for high caspofungin
MICs (Pham et al., 2014). We used Etest R© for the echinocandin
susceptibility testing since it is considered a valuable alternative
to the EUCAST broth microdilution method for routine
susceptibility testing of micafungin in C. glabrata isolates, with
categorical agreement of 96.7% (Bougnoux et al., 2016)
Micafungin and fluconazole MICs were prospectively
determined after isolation with Etest R© strips (Biomerieux, Marcy
L’Etoile, France) according to the manufacturer’s instructions.
Briefly, a pool of five yeast colonies of each isolate was suspended
in 0.9% sterile saline solution to adjust to a turbidity of a 0.5
McFarland standard (Biomérieux). Candida krusei ATCC 6258
and C. parapsilosis ATCC 22019 were used as quality controls.
A broth microdilution reference was used according to the
EUCAST method (Arendrup et al., 2012) to test for susceptibility
to fluconazole and micafungin in vitro using 18 randomly chosen
isolates and 2 isolates showing high micafungin MICs. AM3
medium was used for dilution of micafungin instead of RPMI
due to its better ability to distinguish between mutant and
wild-type isolates for fks protein (Desnos-Ollivier et al., 2008).
C. krusei ATCC 6258 and C. parapsilosis ATCC 22019
were used as quality controls. We used breakpoint tables of
the EUCAST document v8.0 (http://www.eucast.org/clinical_
breakpoints/), which were valid as of November 16, 2015
(European Committee on Antimicrobial Susceptibility Testing
(EUCAST), 2015), and the EUCAST and Etest R© database of MIC
distribution and ECOFFs (http://www.mic.eucast.org). Isolates
were categorized as high fluconazole MICs for MICs > 32
mg/L and high micafungin MICs for MICs > 0.03 mg/L
(Espinel-Ingroff et al., 2016). Notably, some isolates, including
reference strain ATCC MYA 2950 displayed macrocolonies in
the inhibition ellipse of Etest R© after 48 h of incubation with
fluconazole. These macrocolonies were not observed with the
EUCAST technique and were hence not taken into account for
Etest R© interpretation.
MSH2 Sequencing
The first 156 consecutive isolates and the two isolates harboring
high micafungin MICs were selected for MSH2 sequencing.
Twelve primers to cover the 2874 bp gene were used for PCR and
sequencing the amplified DNA and to identifymsh2mutations in
C. glabrata isolates (Supplementary Table 1). Initial amplification
ofMSH2 was performed using 3 couples of primers (33F/1888R;
1013F/2170R; 1914F/2985R) and sequenced with the 12 primers
listed in Supplementary Table 1. PCR was performed in a volume
of 50 µL using 25 µL of ampliTaq Gold 360 MasterMix (Applied
Biosystems, Forster City, USA), isolate extracted DNA (1 ng/µL),
forward primer (0.6 µM), and reverse primer (0.6 µM). The
thermal cycling parameters were as follows: initial denaturation
of 10 min at 95◦C; 35 cycles of 95◦C for 30 s, 55◦C for 30 s, and
72◦C for 1 min 30 s; and a final elongation step at 72◦C for 7 min.
PCR sequencing was performed using BigDye Terminator
v1.1 (Thermo) as recommended by the manufacturer. The
purification of the PCR products was performed using illustra
ExoProStarTM 1-Step (GE Healthcare Life Sciences, Little
Chalfont, UK). Sequencing was performed with all primers
described (Supplementary Table 1) and using a 3500 series
sequencing analyzer (Applied Biosystems, Forster City, USA).
The obtained sequences were compared with the reference wild-
type sequence of C. glabrata MSH2 (GenBank accession number
XM_447585.1) using Geneious v. 8.0 software (Auckland, New
Zealand). Non wild-type sequences are available under the
GenBank accession numbers KY110686–KY110696.
FKS Sequencing
Twelve primers were used for sequencing the two hotspots
regions of the FKS1 and FKS2 genes as described previously
(Zimbeck et al., 2010) of the two isolates harboring high
micafungin MICs and 9 susceptible isolates. PCR was performed
in a volume of 50µLwith 25µL of ampliTaqGold 360MasterMix
(Applied Biosystems, Forster City, USA), isolate extracted DNA
(1 ng/µL), forward primer (0.25 µM), and reverse primer (0.25
µM). The thermal cycling parameters were as follows: initial
denaturation of 10 min at 95◦C; 30 cycles at 95◦C for 30 s,
58◦C for 30 s and 72◦C for 30 s; and a final elongation step at
72◦C for 10 min. The sequencing parameters where similar to
those used for the MSH2 PCR described above. The sequences
were compared with those of a reference strain ATCC 2001
(FKS1 GenBank accession number XM_446406, FKS2 GenBank
accession number XM_448401, and FKS3 GenBank accession
number HQ_845285). Newly described partial FKS sequences are
available under the GenBank accession number KY110697.
MSH2 Polymorphism Phenotyping Assay
A phenotyping assay was used to assess the impact of
MSH2 polymorphisms on the induction of echinocandin
resistance as described previously (Healey et al., 2016). Isolates
harboring the previously undescribed MSH2 polymorphisms
(E7K, P208S/N890I/Y949C, S591Y, E478Q, S346T, and M651T)
were selected and tested. Briefly, the MSH2 sequence was
amplified from the corresponding clinical isolates, expressed on
a yeast centromere plasmid under the control of their native
promoter, and transformed into a laboratory strain carrying a
deletion of MSH2 according to Healey et al. (2016). Forward
mutation frequencies were analyzed by measuring frequencies
of colonies resistant to caspofungin in order to identify whether
the tested MSH2 polymorphism contributed to an increase in
mutation rate and increased emergence of antifungal resistance.
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Short Tandem Repeat (STR) Genotyping
Analysis
Ten previously described STRs markers VNTR2bis, VNTR3,
VNTR4, VNTR5, VNTR6, VNTR8, VNTR9 (Brisse et al., 2009),
GLM5, GLM6 (Abbes et al., 2012), and Cg6 (Grenouillet et al.,
2007) were amplified. The forward primers were tagged with
fluorophores (FAM, HEX, or ATTO565). All PCR reactions
were performed on a GeneAmp PCR System 9700 Thermocycler
(Applied Biosystems) in a final volume of 20 µL containing
1X Ampli Taq Gold buffer (Life technologies) with 0.25 µM
of each primer, 2.5 mM of MgCl2, 0.8 µM of dNTPs, 0.25
UI of Ampli Taq Gold polymerase (Life technologies), and 2
µL of DNA. The reaction consisted of 10 min at 95◦C; 35
cycles of 30 s at 95◦C, 30 s at 55◦C, and 60 s at 72◦C; and a
final extension at 72◦C for 10 min. After amplification, 2 µL
of PCR product was prepared for fragment analysis by adding
18.5 µL of formamide (3700 formamide, Life technologies) and
0.5 µL of Genescan-500 LYZ Size Standard (Life technologies).
Capillary electrophoresis was performed with the denaturing
polymer POP-7 (Life technologies) in a 50-mm capillary tube at
60◦C. The lengths of the PCR fragments were determined on an
ABI 3500 genetic analyzer with ABI Gene mapper v4.1 software
(Applied Biosystems). Rare genotypes were those for which fewer
than 3 isolates/patient were found in our collection. Singletons
are genotypes found in only one isolate of our cohort.
Statistical Analyses and Graphs
All analyses were performed with GraphPad Prism software v6.0
(GraphPad Software, San Diego, CA). Chi-square tests were
used to determine differential repartition in MSH2 mutational
status, in anatomical localization in specific genotypes between
susceptibility groups and to determine resistance. P-values were
determined by a non-parametric t-test. A P< 0.05 (two-tailed) is
considered statistically significant.
RESULTS
Resistance Rate to Fluconazole and
Micafungin
Fluconazole and micafungin Etest R© MICs were determined for
the 268 C. glabrata isolates. The characteristics of the 147 patients
and isolates are summarized in Table 1, and the distributions of
the Etest R© MICs are presented in Figure 1. MIC50 and MIC90
were 16 mg/L and 256 mg/L for fluconazole and 0.016 mg/L
and 0.023 mg/L for micafungin, respectively. Fluconazole MICs
> 32 mg/L occurred in 42 (15.7%) of the 268 isolates. Two
isolates (0.7%) had micafungin MICs > 0.032 mg/L (isolates #96
[0.047 mg/L] and #230 [0.25 mg/L]). Isolate #96 exhibited both
high fluconazole and micafungin MICs. Essential agreement (±
2 dilutions) for fluconazole and micafungin MICs was observed
for the 20 isolates tested with Etest R© and EUCASTmethods (data
not shown). EUCASTMICs for isolates #96 and #230 were 64 and
8 mg/L for fluconazole and 0.03 and 0.25 mg/L for micafungin,
respectively.
The two hotspots of the three FKS genes of the two isolates
harboring high micafungin MICs were sequenced and revealed
mutation K1323T in HS2 of FKS1 for isolate #96 and mutation
FKS2-F6581 in HS1 of FKS2 for isolate #230. Notably, the nine
randomly selected isolates without high micafungin MICs had
wild-type sequence for FKS genes.
Impact of Drug Exposure on Antifungal
Resistance
The duration of exposure and the date of initiation of
caspofungin, voriconazole, and posaconazole within the past
6 months before sampling was recorded for all patients. Pre-
exposed isolates were defined as isolates recovered from patients
exposed for at least 7 days to antifungal drugs (treatment began
≥ 7 days before sampling). Voriconazole and posaconazole pre-
exposure was significantly associated with recovery of isolates
with fluconazole MICs> 32mg/L (P< 0.001). The proportion of
isolates harboring fluconazole MICs> 32 mg/L was significantly
higher (20/41, 48.8%) among isolates exposed to triazoles
than among unexposed isolates (23/227, 10.1%). Pre-exposure
to caspofungin was also significantly associated with higher
occurrence of resistance to micafungin (P = 0.007), with two
isolates having high micafungin MICs among the 23 isolates
exposed to caspofungin. The patient with isolate #230 suffered
from extensive burns and was treated with caspofungin and
voriconazole for invasive skin infection due to molds. Recurrent
mouth and skin swabs showed the emergence of echinocandin
resistant C. glabrata after 8 days of treatment. Patient with
isolate #96 received caspofungin, but data concerning duration
of treatment were lacking.
Impact of Mutator Genotype on Antifungal
Resistance
MSH2 sequencing was performed for the first 156 isolates
and two micafungin resistant isolates (90 patients). Overall,
69 (44%) isolates harbored non-synonymous polymorphisms
within MSH2 gene as compared with the ATCC 2001
reference strain (GenBank accession number: XM_447585.1).
Non-synonymous msh2 polymorphisms led to several amino
acid changes: P208S/N890I (n = 17), V239L/A942T (n =
14), V239L (n = 11), E7K (n = 9), and E456D (n = 8;
Table 2). One isolate harboring a pure microsatellite genotype
(one allele per marker) had two different MSH2 genotypes
P208S/N890I and V239L/A942T upon sequencing (double peaks
at specific positions). Notably, micafungin-resistant isolates #96
and #230 displayed P208S/N890I andwild-typeMSH2 sequences,
respectively.
Overall, MSH2 non-synonymous polymorphisms were
observed in 48% (12/25) of the isolates harboring high
fluconazole MICs and 42.8% (57/133) of isolates harboring
low fluconazole MICs (P = 0.66). To avoid any biases in this
analysis, we selected one more isolate per genotype per patient
(111 isolates, 90 patients) in order to avoid counting the same
genotype several times in a given patient. In this situation, no
significant association was observed (MSH2 non-synonymous
polymorphisms were observed in 62.5% (10/16) of the isolates
harboring high fluconazole MICs and 49.5% (47/95) of isolates
harboring low fluconazole MICs (P = 0.42)). To enable
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FIGURE 1 | Distribution of fluconazole (A) and micafungin (B) MICs using Etest® for 268 clinical isolates of C. glabrata from 147 patients. Dotted line shows
recently published EUCAST breakpoints for C. glabrata susceptibility.
comparison with data presented in Healey et al. (2016), no
significant association was also observed when the threshold for
fluconazole resistance was considered as MIC ≥ 32 mg/L.
Relationship between Mutator Genotype
and Short Tandem Repeat Genotype
Genotyping analysis of the 268 isolates determined by validated
microsatellite genotyping (10 markers) revealed the presence of
49 genotypes (Gt) (median number of isolates per genotypes= 1,
range= 1–18). Rare (≤ 3 isolates per genotype) and frequent (>3
isolates per genotype) genotypes represented 43 minor genotypes
(median 1, interquartile [1–1]) and 9 major genotypes (median
4, interquartile [3–6], range [1–18]). Among the 156 isolates
sequenced for MSH2, 101 isolates, corresponding to one isolate
per genotype per patient, were selected to analyze the correlation
between microsatellite genotype and MSH2 sequence. From
these 49 genotypes, 44 were considered rare (≤3 isolates per
genotype) and 5 frequent (>3 isolates per genotype). Association
between MSH2 polymorphism and genotype exists since in the
17 genotypes found more than once in our collection, 13 (76%)
harbored the same MSH2 polymorphism in all isolates from a
specific genotype (Table 3).
In our collection, wild-type isolates harbored 26 different
genotypes (including 19 singletons). We found the E7K isolates
in one genotype (Gt1), P208/N890I in 11 genotypes (including
7 singletons), E456D in 1 genotype (Gt30), V239L/A942T in 6
genotypes (including 2 singletons), and V239L in 4 genotypes.
The seven isolates harboring other MSH2 sequences were found
in 7 genotypes (including 4 singletons). Notably, M651T isolates
were found in 2 singletons. In total, there was a significant
differential distribution of MSH2 polymorphisms in rare and
frequent genotypes (P= 0.004, Table 3).
Impact of MSH2 Mutations on Mutator
Phenotype
To assess the impact of MSH2 polymorphisms on the induction
of echinocandin resistance, a phenotyping assay was used as
previously described (Healey et al., 2016). Wild-type or MSH21
FIGURE 2 | Impact of MSH2 mutations on mutator phenotype. Wild-type
or MSH21 cells expressing an empty or MSH2-containing plasmid were
selected on caspofungin. Frequency data are mean ± standard deviation (s.d.)
from three independent experiments; representative images are shown.
P-values determined by student’s t-test. A P < 0.05 (two-tailed) is considered
statistically significant.
cells expressing an empty or mutated MSH2-containing plasmid
were selected on agar plates containing 1 mg/L of caspofungin
(8 to 32-fold above wild type MICs). Upon caspofungin
selection in vitro, MSH21 exhibited a hyper-mutable phenotype
consistent with previous findings (Healey et al., 2016) (average
caspofungin resistant colony frequency = 3.47E-7 ± 6.64E-
8). Several MSH2 polymorphisms (E478Q, S346T, M651T)
found in our clinical isolates demonstrated moderate increases
in caspofungin-resistant colony frequencies (4- to 5-fold vs.
wild type), although the differences were not significant (P >
0.05) (Figure 2, Supplementary Table 2). However, the MSH2-
P208S/N890I/Y949C andMSH2-S591Y alleles did exhibit greater
increases (9 to 10-fold vs. wild type) in colony frequencies and an
increasing trend (average caspofungin resistant colony frequency
= 2.17E-7 ± 7.65E-8 and 1.98E10-7 ± 1.04E-7; P = 0.07 and
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TABLE 2 | Fluconazole MIC distribution of 158 isolates according to MSH2 genotype.
Etest MICs
(mg/L)
WT P208S/
N890I
V239L/
A942T
V239L E7K E456D M651T S591Y V34E/
V239L/
A942T
P208S/
N890I/
Y949C
S346T E478Q
GenBank
accession number
KY110692 KY110686 KY110688 KY110687 KY110690 KY110696 KY110689 KY110693 KY110691 KY110694 KY110695
%R 14.8 23.5 0.0 18.2 11.1 0.0 100.0 0.0 100.0 0.0 0.0 100.0
3 1
4 5
6 3 2 2
8 8 1 5
12 9 3 1 2 3 1 1
16 17 3* 3* 3 3 2 1 1
24 16 2 2 2 1 4 1
32 18 5 1 1 1
48 3 2 1
64 4
256 6 2 1 1 3 1 1
Total 89 18* 15* 11 9 8 3 2 1 1 1 1
WT, wild-type; %R, percentage of isolates resistant to fluconazole (CMI > 32 mg/L) among genotype. *Of note, one isolate (Fluconazole MIC = 16mg/L) harbored a mixture of the
P208S/N890I and V239L/A942T MSH2 sequences and a unique microsatellite genotype (Gt18).
TABLE 3 | Genotype distribution of 101 isolates (one isolate per genotype per patient) according to the most frequent MSH2 genotype.
Gt (n) WT n (%) E7K n (%) P208S/N890I n (%) E456D n (%) V239L/A942T n (%) V239L n (%) Other n (%)
Frequent genotypes Gt1 (19) 15 (88) 3 (16) 1 (6) S346T
(5 genotypes, Gt2 (4) 4 (100)
41 isolates) Gt10 (5) 4 (80) 1 (10) V34E/V239L/A942T
Gt18 (5) 5 (100) 1 (10) N890I/A942T*
Gt30 (8) 8 (100)
Rare genotypes Gt4 (3) 3 (100)
(44 genotypes, Gt32 (3) 3 (100)
60 isolates) Gt36 (3) 2 (66.6) 1 (33.3)
Gt45 (3) 3 (100)
Gt3 (2) 2 (100)
Gt5 (2) 2 (100)
Gt6 (2) 2 (100)
Gt7 (2) 2 (100)
Gt8 (2) 2 (100)
Gt22 (2) 1 (50) 1(50)
Gt23 (2) 2 (100)
Gt41 (2) 2 (100)
Singletons (32) 19 (59) 7 (22) 2 (6) 1 (3) P208S/N890I/Y949C;
2 (6) M651T; 1 (3) E478Q
*One isolates harboring Gt18 was a mixture of N890I/A942T and P208S/N890I sequences.
P= 0.06, respectively).MSH2-E7K yielded caspofungin resistant
colonies similar to wild type.
DISCUSSION
In our cohort, we found an intermediate level of resistant isolates
to fluconazole (15.7%) and low level of resistance to micafungin
(0.7%) using Etest R© testing and EUCAST breakpoints, with
only 1/268 isolates showing cross-resistance to both antifungal
classes. There were 28 patients (19.0%) with at least one isolate
with high fluconazole MIC, one patient (0.7%) with high
micafungin MIC, and one patient (0.7%) with high fluconazole
and high micafungin MICs. The resistance rate of C. glabrata to
fluconazole (15.7%) builds on previous studies showing similar
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rates. Worldwide studies from 1997 to 2005 describe resistance
rates of 14.3–19.2% with no consistent trend toward increasing
resistance to fluconazole (Pfaller et al., 2007).
The prevalence of echinocandin resistance is consistent with
that found in other European studies. Studies showed 1.5%
resistance in a cohort of 64 bloodstream isolates in two university
hospitals in Germany and Austria (Klotz et al., 2016), none in
Spain and Italy from 79 bloodstream isolates (Bassetti et al.,
2013), 2.1% of 94 invasive isolates obtained from Lombardy, Italy
(Tortorano et al., 2013), and 1% of 193 isolates obtain from urine
samples from France (Bourgeois et al., 2014). In the USA, the
prevalence was between 2 and 4% to echinocandins from 1997
to 2000 (Castanheira et al., 2016).
The alarming increase in echinocandin resistance observed
in the USA began in the last 10 years (Alexander et al., 2013;
Vallabhaneni et al., 2015), but it does not seem to concern
Europe. In addition, the prevalence in the USA seems to
change from one center to another with a proportion varying
from 0 to 25% of resistant isolates (Vallabhaneni et al., 2015),
depending on the patient population and the presence of specific
antifungal stewardship (Pfaller and Diekema, 2007; Vallabhaneni
et al., 2015). The main risk factor for developing resistance to
echinocandin is prior and prolonged exposure (Thompson et al.,
2008; Dannaoui et al., 2012; Beyda et al., 2014; Vallabhaneni
et al., 2015). This is well illustrated in our cohort, with two
patients showing echinocandin resistant isolates out of 23 pre-
exposed to echinocandin. However, it mostly required prolonged
and repeated treatment (Thompson et al., 2008; Fekkar et al.,
2014) with echinocandins, it can emerge shortly after treatment
initiation (Lewis et al., 2013).
FKS-sequencing of isolate #230 revealed a previously
described mutation in FKS2 (Fks2-658delF) (Jensen et al., 2015;
Healey et al., 2016). The FKS1 K1323T mutation found in #96
has never been described to our knowledge. This mutation is
located upstream of the DWVRRYTL FKS1 hotspot, suggesting
an implication in echinocandin resistance, but a glucan synthase
inhibition assay should be implemented to help confirm the
resistance.
We observed an increased proportion of colonizing
isolates with high fluconazole MICs in patients who received
voriconazole or posaconazole for more than 7 days. Indeed,
all patients at risk of candidiasis under triazole prophylaxis or
treatment for invasive or non-invasive fungal infections should
be considered at risk for fluconazole resistant C. glabrata isolates.
The kinetics of disappearance of these resistant colonizing
isolates, whether they are resistant to azoles or echinocandins, is
not known and would not be predictable. An important bias of
our study is the lack of data concerning the use of fluconazole, the
most common azole antifungal agent, because the consumption
of this molecule is not prospectively monitored in our hospital.
This should underestimate the rate of resistance acquired in
isolates pre-exposed to triazoles.
The association of MSH2 mutation and mutator phenotype
with an increased emergence of antifungal resistance has recently
been established (Healey et al., 2016). However, this study did
not focus on clinical facts and treatment history, although
individual center differences were noted. Several centers did
not demonstrate significant differences between resistant and
susceptible isolates when grouped according to MSH2 genotype,
while others did (Healey et al., 2016). Indeed, MSH2 mutation
might be better associated with multidrug resistance, which was
not observed in this study. Among the most frequent mutations,
P208S/N890I, V239L, and E231G/L269F were associated with
an increased emergence of caspofungin-resistant colonies, while
E456D was not (Healey et al., 2016). They observed a greater
rate ofMSH2mutation among fluconazole-resistant (≥32 mg/L)
isolates than among susceptible ones (65 vs. 52%; P= 0.04).
In our study, using cut-offs of >32 mg/L (EUCAST
recommendation) and ≥32 mg/L (Healey et al., 2016), we did
not find a significant association between MSH2 mutations and
fluconazole resistance, although we observed the same most
frequent mutations in our isolates, P208S/N890I, V239L/A942T,
and V239L. However, we did not observe the mutation
E231G/L269F and found one unknown mutation (E7K) in
notable proportion that had not been previously analyzed for its
role in MMR activity. E7K isolates were associated with a rate of
11% fluconazole-resistant strains (Table 3). Experimentally, E7K
mutator phenotype is similar to that of the wild-type and E456D
isolates, suggesting a conservative mutation (Healey et al., 2016).
Although the P208S/N890I/Y949C and S591Y mutants show
a slight increase in frequency of caspofungin-resistant colonies,
they could not be assigned to the mutator phenotype. Other
mechanisms could rely on other genes involved in mismatch
repair, such as PMS1 or RAD50, a double strand break repair
gene. Both genes were implicated in the mutator phenotype in C.
albicans (Legrand et al., 2007). Considering the small proportion
(2/268) of isolates showing resistance to echinocandin out of our
268 isolates, we were not able to interpret the impact of MSH2
mutations on echinocandin resistance. Microsatellite genotyping
analysis of the isolates showed a significant association between
MSH2 mutations and the short tandem repeat genotypes
(frequent or rare) (P = 0.009, Table 3). This suggests that
MSH2 could be a genotyping hallmark rather than an indicator
of fluconazole resistance acquisition risk. Indeed, MSH2 could
be considered as one of the yeast’s housekeeping genes, and
sequence variations in this gene could be related to differences
in the genetic complex rather than a direct link to fluconazole
resistance.
Alternatively, the elevated rates of MSH2 genotypes that
do demonstrate partial loss of function may facilitate the
pathogenesis of C. glabrata through acquisition of mutations
that increase fitness or virulence. In agreement with the data
presented here, Healey and colleagues recently described that
MSH2 genotypes largely correspond to strain type as measured
by multi-locus sequence typing (Healey et al., unpublished
data). Additionally, sequence types associated withMSH2 partial
loss of function genotypes, including E231G/L269F (ST16) and
P208S/N890I (ST10), are among the most frequently identified
in at least two American cities (Lott et al., 2010). This further
highlights the differences in strain distribution between the U.S.
and Europe and potentially provides insight into differences in
resistance rates.
In summary, we found a low prevalence rate of resistance
to echinocandins and fluconazole for C. glabrata in comparison
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with data from North America. In our study, resistance was
a consequence of previous exposure to antifungal drugs. This
difference in prevalence should be explained by different medical
care habits and recommendations. MSH2 mutations alone
cannot explain why C. glabrata exhibits a rapid acquisition of
resistance compared to other Candida spp. MSH2 seems to be
associated with the STR genotype and could be a simple marker
of the genetic group of a strain.
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